These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31648843)

  • 41. Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment.
    Chabrol H; Peresson G; Bonnet D
    Am J Psychiatry; 1999 Mar; 156(3):497-8. PubMed ID: 10080578
    [No Abstract]   [Full Text] [Related]  

  • 42. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics.
    Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Blonanserin in the treatment of schizophrenia].
    Tenjin T; Miyamoto S
    Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia.
    Friedman JI; Ocampo R; Elbaz Z; Parrella M; White L; Bowler S; Davis KL; Harvey PD
    J Clin Psychopharmacol; 2005 Jun; 25(3):237-42. PubMed ID: 15876902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
    Newman-Tancredi A; Cussac D; Depoortere R
    Curr Opin Investig Drugs; 2007 Jul; 8(7):539-54. PubMed ID: 17659474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
    Kessler RM
    Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411
    [No Abstract]   [Full Text] [Related]  

  • 47. The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment.
    Ribeiro-Santos R; de Campos-Carli SM; Ferretjans R; Teixeira-Carvalho A; Martins-Filho OA; Teixeira AL; Salgado JV
    Nord J Psychiatry; 2020 Apr; 74(3):187-193. PubMed ID: 31738648
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
    Borison RL
    Acta Psychiatr Scand Suppl; 1996; 389():5-11. PubMed ID: 8985471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs.
    McCreary AC; Newman-Tancredi A
    Curr Pharm Des; 2015; 21(26):3725-31. PubMed ID: 26044980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different MK-801 administration schedules induce mild to severe learning impairments in an operant conditioning task: role of buspirone and risperidone in ameliorating these cognitive deficits.
    Rapanelli M; Frick LR; Bernardez-Vidal M; Zanutto BS
    Behav Brain Res; 2013 Nov; 257():156-65. PubMed ID: 24095879
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repurposing Drugs for Cognition in Schizophrenia.
    Yang YS; Marder SR; Green MF
    Clin Pharmacol Ther; 2017 Feb; 101(2):191-193. PubMed ID: 27706797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. British Association for Psychopharmacology--2008 Summer Meeting.
    Jenkins TA
    IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070
    [No Abstract]   [Full Text] [Related]  

  • 53. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
    Tuplin EW; Holahan MR
    Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Buspirone for autistic disorder in a woman with an intellectual disability.
    Brahm NC; Fast GA; Brown RC
    Ann Pharmacother; 2008 Jan; 42(1):131-7. PubMed ID: 18056831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anxiety disorder.
    Gale C; Oakley-Browne M
    BMJ; 2000 Nov; 321(7270):1204-7. PubMed ID: 11073514
    [No Abstract]   [Full Text] [Related]  

  • 56. Buspirone Counteracts MK-801-Induced Schizophrenia-Like Phenotypes through Dopamine D
    Torrisi SA; Salomone S; Geraci F; Caraci F; Bucolo C; Drago F; Leggio GM
    Front Pharmacol; 2017; 8():710. PubMed ID: 29046641
    [No Abstract]   [Full Text] [Related]  

  • 57. Interaction of Dopamine D2 and 5-HT1A Receptor Partial Agonism on Antipsychotic Efficacy.
    Lloyd H; Deng C
    J Clin Psychopharmacol; 2016 Apr; 36(2):192-3. PubMed ID: 26848788
    [No Abstract]   [Full Text] [Related]  

  • 58. The influence of impaired processing speed on cognition in first-episode antipsychotic-naïve schizophrenic patients.
    Andersen R; Fagerlund B; Rasmussen H; Ebdrup BH; Aggernaes B; Gade A; Oranje B; Glenthoj B
    Eur Psychiatry; 2013 Aug; 28(6):332-9. PubMed ID: 22999439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.
    Dean B; Scarr E
    Curr Drug Targets CNS Neurol Disord; 2004 Jun; 3(3):217-25. PubMed ID: 15180482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.